Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support
- PMID: 23362894
- DOI: 10.1177/0310057X1304100112
Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support
Abstract
Extracorporeal membrane oxygenation (ECMO) is known to affect pharmacokinetics and hence optimum dosing. The aim of this open label, prospective study was to investigate the pharmacokinetics of oseltamivir (prodrug) and oseltamivir carboxylate (active metabolite) during ECMO. Fourteen adult patients with suspected or confirmed H1N1 influenza were enrolled in the study. Oseltamivir 75 mg was enterally administered twice daily and blood samples for pharmacokinetic assessment were taken on day 1 and 5. A multi-compartmental model to describe the pharmacokinetics of oseltamivir and oseltamivir carboxylate was developed using a non-linear mixed effects modelling approach. The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults. The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients. Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54-1277) ng/ml, respectively. Both area under the curve and Cmax were significantly correlated with serum creatinine (r2=0.37, P=0.02 and r2=0.29, P=0.02, respectively). Systemic exposure to oseltamivir carboxylate following the administration of enteral oseltamivir 75 mg twice daily in adult ECMO patients is comparable to those in ambulatory patients and far in excess of concentrations required to maximally inhibit neuraminidase activity of the H1N1 virus. Dosage adjustment for ECMO, per se, appears not to be necessary; however, doses should be reduced in patients with renal dysfunction.
Similar articles
-
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.Pharmacotherapy. 2012 Dec;32(12):1061-9. doi: 10.1002/phar.1151. Pharmacotherapy. 2012. PMID: 23208833
-
Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.Ther Drug Monit. 2012 Apr;34(2):171-5. doi: 10.1097/FTD.0b013e318248672c. Ther Drug Monit. 2012. PMID: 22354159
-
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.CMAJ. 2010 Mar 9;182(4):357-63. doi: 10.1503/cmaj.092127. Epub 2010 Feb 16. CMAJ. 2010. PMID: 20159892 Free PMC article.
-
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clin Pharmacokinet. 2010 Nov;49(11):741-65. doi: 10.2165/11534730-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923248 Review.
-
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.J Antimicrob Chemother. 2010 Apr;65 Suppl 2(Suppl 2):ii5-ii10. doi: 10.1093/jac/dkq015. J Antimicrob Chemother. 2010. PMID: 20215135 Free PMC article. Review.
Cited by
-
Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs.J Clin Med. 2023 May 29;12(11):3748. doi: 10.3390/jcm12113748. J Clin Med. 2023. PMID: 37297946 Free PMC article. Review.
-
Bioavailability of Orally Administered Drugs in Critically Ill Patients.J Pharm Pract. 2023 Aug;36(4):967-979. doi: 10.1177/08971900221100205. Epub 2022 May 6. J Pharm Pract. 2023. PMID: 35521821 Free PMC article.
-
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review.Drugs. 2021 Jul;81(11):1307-1329. doi: 10.1007/s40265-021-01557-3. Epub 2021 Jul 5. Drugs. 2021. PMID: 34224115
-
Influenza virus-related critical illness: prevention, diagnosis, treatment.Crit Care. 2019 Jun 12;23(1):214. doi: 10.1186/s13054-019-2491-9. Crit Care. 2019. PMID: 31189475 Free PMC article. Review.
-
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.Clin Infect Dis. 2019 Mar 5;68(6):e1-e47. doi: 10.1093/cid/ciy866. Clin Infect Dis. 2019. PMID: 30566567 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical